Company Profile
Lantheus Holdings, Inc. Stock Price, News & Analysis
- Ticker:
- LNTH
- Exchange:
- NASDAQ
- Sector:
- Radiopharmaceuticals, Oncology
- Location:
- United States
Stock performance
101.07 USD (-0.42%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, LNTH closed down 0.42% at $101.07. No new same-company headline was identified in the current news window.
Company overview
Radiopharmaceutical-Focused Platform
Lantheus is a radiopharmaceutical-focused company that develops and commercializes diagnostic imaging agents and targeted radiotherapeutics. Its “Find, Fight and Follow” strategy spans disease detection, treatment and longitudinal monitoring, supported by approximately 70 years of experience in radiopharmaceutical development and supply.
PSMA PET Imaging Franchise
PYLARIFY is an F-18 prostate-specific membrane antigen PET imaging agent used to detect PSMA-positive lesions in patients with prostate cancer. It is Lantheus’ largest commercial product and anchors the company’s oncology radiodiagnostic business. PYLARIFY TruVu is a newly approved formulation designed to improve manufacturing efficiency and supply flexibility across the company’s PET manufacturing network.
Neuroendocrine Tumor Portfolio
LNTH-2501 is an investigational gallium-68 edotreotide PET imaging kit for localizing somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. PNT2003 is a lutetium-177 dotatate radiotherapeutic that has received tentative FDA approval and is intended to become the first radioequivalent treatment for gastroenteropancreatic neuroendocrine tumors, subject to final approval and resolution of applicable patent matters.
Alzheimer’s Disease Imaging
Lantheus is expanding its neurology business through an Alzheimer’s disease imaging portfolio led commercially by Neuraceq. Additional assets, including MK-6240 and NAV-4694, support the company’s broader strategy of supplying PET imaging tools for the detection and characterization of Alzheimer’s-related pathology in clinical care and therapeutic development.
Cardiac Ultrasound Imaging
DEFINITY is an ultrasound-enhancing agent used to improve visualization during echocardiography. The product provides Lantheus with an established cardiology franchise outside radiopharmaceutical imaging and contributes recurring demand through routine diagnostic use.
Focused PET and Theranostics Strategy
Lantheus divested its legacy SPECT business to concentrate resources on PET radiodiagnostics and simplify its operating model. The company is prioritizing radiodiagnostic commercialization, manufacturing-network expansion and Alzheimer’s imaging while evaluating value-maximizing development or partnership paths for its radiotherapeutic assets.
Future catalysts
FDA action on LNTH-2501 for somatostatin receptor-positive neuroendocrine tumor imaging expected by June 29, 2026.
Phased geographic launch of PYLARIFY TruVu planned to begin in the fourth quarter of 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lantheus Holdings, Inc. (LNTH)?
Lantheus Holdings, Inc. (LNTH) most recently closed at 101.07 USD, a -0.42% move versus the previous session.
What does Lantheus Holdings, Inc. do?
Radiopharmaceutical-Focused Platform Lantheus is a radiopharmaceutical-focused company that develops and commercializes diagnostic imaging agents and targeted radiotherapeutics. Its “Find, Fight and Follow” strategy spans disease detection, treatment and longitudinal monitoring, supported by approximately 70 years of experience in radiopharmaceutical...
On which exchange is LNTH stock listed?
Lantheus Holdings, Inc. (LNTH) is associated with NASDAQ, United States, Radiopharmaceuticals, Oncology.
What is LNTH-2501?
FDA action on LNTH-2501 for somatostatin receptor-positive neuroendocrine tumor imaging expected by June 29, 2026.
Which conditions is Lantheus Holdings, Inc. targeting with LNTH-2501?
Lantheus Holdings, Inc. is associated with oncology, cancer therapeutics, neurology based on its company overview and current catalyst commentary.
How does Lantheus Holdings, Inc. describe recent progress with LNTH-2501?
FDA action on LNTH-2501 for somatostatin receptor-positive neuroendocrine tumor imaging expected by June 29, 2026.
What is MK-6240?
Additional assets, including MK-6240 and NAV-4694, support the company’s broader strategy of supplying PET imaging tools for the detection and characterization of Alzheimer’s-related pathology in clinical care and therapeutic development.
What should investors watch for with MK-6240?
FDA action on LNTH-2501 for somatostatin receptor-positive neuroendocrine tumor imaging expected by June 29, 2026. Phased geographic launch of PYLARIFY TruVu planned to begin in the fourth quarter of 2026.